Caminha Raquel D'Aquino Garcia, Chicrala Gabriela Moura, Soares Júnior Luiz Alberto Valente, Santos Paulo Sérgio da Silva
Faculdade de Odontologia de Bauru, Universidade de São Paulo, Bauru, SP, Brazil.
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
Einstein (Sao Paulo). 2019 Jul 18;17(3):eRW4628. doi: 10.31744/einstein_journal/2019RW4628.
To establish the profile of patients who developed antiangiogenic agent-related osteonecrosis of the jaws, and identify the treatments currently used in dental management. We searched the PubMed®/Medline® and Scopus databases using the words "osteonecrosis AND antiangiogenic therapy", with the following inclusion criteria: articles published in English, case reports, available online, and for an unlimited period. Of the 209 articles retrieved, 18 were selected, for a total of 19 case reports, since one article included two cases that met the inclusion criteria for this study. Medication-related osteonecrosis of the jaws is characterized by exposure of necrotic bone in the oral cavity that does not heal over a period of 8 weeks in patients with no previous history of radiation therapy. Antiangiogenic drugs are indicated in the treatment of certain tumors, since they stop the formation of new blood vessels, controlling tumor growth and the chance of metastasis. Dental prevention is essential in patients who will be put on antiangiogenic agents, to minimize the risk for osteonecrosis.
为明确发生抗血管生成剂相关颌骨骨坏死的患者特征，并确定目前牙科治疗中所采用的治疗方法。我们使用“骨坏死 AND 抗血管生成治疗”检索了PubMed®/Medline®和Scopus数据库，纳入标准如下：英文发表的文章、病例报告、可在线获取且发表时间不限。在检索到的209篇文章中，选取了18篇，共计19例病例报告，因为有一篇文章包含两例符合本研究纳入标准的病例。药物相关性颌骨骨坏死的特征为口腔内坏死骨暴露，在无既往放疗史的患者中，8周内未愈合。抗血管生成药物用于某些肿瘤的治疗，因为它们可阻止新血管形成，控制肿瘤生长和转移几率。对于将接受抗血管生成剂治疗的患者，牙科预防至关重要，可将骨坏死风险降至最低。
